Author

Eric J. Niesor

Observed names: E J Niesor, E Niesor, E. J. Niesor, E. NIESOR, E. Niesor, E.J. Niesor, EJ Niesor, Eric J Niesor, Eric Joseph Niesor, Eric Niesor, Joseph Eric Niesor, Niesor, E.J.

Observed institutions: University of Geneva, Roche (Switzerland), Montreal Heart Institute, Denver VA Medical Center, Bibliothèque de Genève, Research on healthcare performance, DalCor Pharmaceuticals (Canada), NewAmsterdam Pharma (Netherlands), European Organization for Nuclear Research, Université de Montréal, University of Colorado Denver

ORCID: 0000-0003-2923-2027

Observed ORCID: 0000-0003-2923-2027

OpenAlex ID: A5083604698

A New Selective Peroxisome Proliferator-Activated Receptor γ Antagonist with Antiobesity and Antidiabetic Activity

2002 · Jennifer Rieusset, Fethi Touri, et al. · Molecular Endocrinology · 214

PDF

Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

2015 · Jean-Claude Tardif, Eric Rhéaume, et al. · Circulation Cardiovascular Genetics · 185

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro

2005 · Elke Burgermeister, Astride Schnoebelen, et al. · Molecular Endocrinology · 160

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

2010 · Eric J. Niesor, Christine Magg, et al. · Journal of Lipid Research · 152

PDF

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

2017 · Robert S. Rosenson, H. Bryan Brewer, et al. · Nature Reviews Cardiology · 148

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.

2009 · Evan A. Stein, Erik S.G. Stroes, et al. · The American Journal of Cardiology · 137

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

2014 · Kausik K. Ray, Marc Ditmarsch, et al. · European Heart Journal · 88

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport

2007 · Urbain Tchoua, Wilissa D'Souza, et al. · Cardiovascular Research · 73

PDF

Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein

2015 · Eric J. Niesor, Gregory G. Schwartz, et al. · Cardiovascular Drugs and Therapy · 69

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

2010 · Roger G Clerc, Andrea Stauffer, et al. · Journal of Hypertension · 64

Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study

2012 · Christie M. Ballantyne, Michael Miller, et al. · American Heart Journal · 58

gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity

1987 · Nguyen Lan Mong, Eric Niesor, et al. · Journal of Medicinal Chemistry · 54

Dalcetrapib: no off‐target toxicity on blood pressure or on genes related to the renin‐angiotensin‐aldosterone system in rats

2009 · ESG Stroes, JJP Kastelein, et al. · British Journal of Pharmacology · 50

The Nuclear Receptors FXR and LX alpha Potential Targets for the Development of Drugs Affecting Lipid Metabolism and Neoplastic Diseases

2001 · Eric Niesor, Jean Flach, et al. · Current Pharmaceutical Design · 49

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism

2011 · Eric J. Niesor · Current Opinion in Lipidology · 47

The Novel Cholesterol-lowering Drug SR-12813 Inhibits Cholesterol Synthesis via an Increased Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase

1996 · Theo A. Berkhout, Helen M. Simon, et al. · Journal of Biological Chemistry · 45

PDF

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients

2013 · Guido Franceschini, Elda Favari, et al. · Journal of clinical lipidology · 43

Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?

2015 · Alaa Othman, Renee Benghozi, et al. · Journal of clinical lipidology · 41

Effect of Compounds Affecting ABCA1 Expression and CETP Activity on the HDL Pathway Involved in Intestinal Absorption of Lutein and Zeaxanthin

2014 · Eric J. Niesor, Evelyne Chaput, et al. · Lipids · 39

The Nuclear Oxysterol Receptor LXRα Is Expressed in the Normal Human Breast and in Breast Cancer

2004 · D. M. Vigushin, Y. Dong, et al. · Medical Oncology · 33

Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP

2016 · Matthias E. Lauer, Alexandra Graff-Meyer, et al. · Journal of Structural Biology · 32

PDF

Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.

2001 · D S Alberts, A V Hallum, et al. · PubMed · 30

The Mevalonate/Isoprenoid Pathway Inhibitor Apomine (SR-45023A) Is Antiproliferative and Induces Apoptosis Similar to Farnesol

2000 · Jean Flach, Isabelle Antoni, et al. · Biochemical and Biophysical Research Communications · 30

Apomine, a Novel Hypocholesterolemic Agent, Accelerates Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase and Stimulates Low Density Lipoprotein Receptor Activity

2004 · Joseph Roitelman, Danièle Masson, et al. · Journal of Biological Chemistry · 29

SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis

1997 · Theo A Berkhout, Helen M Simon, et al. · Atherosclerosis · 25

Works count: 112

Citation count: 2,305

H-index: 25

I10-index: 44